These are good questions and I look forward to Dr T's answers.
I would add only that my understanding is that the RC110 formulation remains the one which will continue to be used for blood cancers, so it won't be obsolete after RC220 is shown to be safe and effective for solid cancers. Happy to be corrected.
Ann: December 2023 Preclinical & Clinical Program Update, page-65
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $179.8K | 108.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1437 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 3313 | 1 |
View Market Depth
| Last trade - 15.58pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |